🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We have fascinating new tools to interrogate cancer immunity. Another post #ESMO19 read nature.com/articles/s4157…

Epigenetics is at the road cross of some many other anticancer therapies. This is the correct link to the paper herebelow nature.com/articles/s4157…

How important are tumor-associated neutrophils in cancer? Check out this review NatureRevClinOncol nature.com/articles/s4157…

Optimizing the management of adverse events of #immunotherapy NatureRevClinOncol nature.com/articles/s4157…

Excellent work led by our very talented oncology fellow Natalie Vokes Natalie Vokes at Dana-Farber with Eli Van Allen and in collaboration with MSKCC.

Probably it is not perfect and complete, but it just wants to show all the therapeutics improvements achieved for advanced lung cancer in the recent year. This algorithm will be more full (and complicated) at the end of 2020 working all together!! #LCSM

New report of Exon 16–Skipping HER2 as a mechanism of resistance in #EGFR L858R/T790M+ #NSCLC post-osimertinib; very important to remember to obtain molecular sequencing at the time of PD JTO & JTO CRR #LCSM bit.ly/2tlg1Jo

Excellent editorial by Chul Kim, Stephen V Liu, MD on the 1st line use of EGFR TKIs in NSCLC: "EGFR TKIs achieved the previously unthinkable: they replaced first-line chemotherapy for some patients with advanced NSCLC." Plus, looking ahead to chemo+TKI trials academic.oup.com/annonc/article…

Osimertinib in patients with non-small cell lung cancer with uncommon EGFR mutations bit.ly/2F0PVho #lcsm #JCO

#ESMO20 Grateful for the chance to present characterization of long-term #SCLC survivors with atezolizumab and carboplatin/etoposide in IMpower 133. #LCSM IASLC OncoAlert

Welcome to 4th Gen EGFR inhibitors! BLU-945 hits triple mutant EGFR+/T790M/C797S, alone and in combo (fig B and A, adapted from 1296P). Triple mut are seen in EGFRmut NSCLC treated with 1st/2nd Gen followed by osimertinib (usually T790M is lost after osi 1st line). #ESMO20 #LCSM

Promising perspectives for EGFR mutant #lcsm #ESMO20 with 4th generation EGFR TKI that can block triple mutant EGFR/T790M/C797S

This review in Cancer Discovery describes the most common mechanisms of resistance to targeted therapies & #immunotherapy & discusses challenges for overcoming #resistance #PrecisionMedicine Fabrice Barlesi FabriceAndre Mihaela Aldea cancerdiscovery.aacrjournals.org/content/11/4/8…

Fascinating paper of mechanisms of #resistance to KRASG12C inhibitors: 1) polyclonal RAS-MAPK reactivation 1 2) KRAS switch-II pocket mutation that impairs binding cancerdiscovery.aacrjournals.org/content/early/…

Developing personalized cancer vaccines. A great review in NatureRevClinOncol #personalized #immunotherapy nature.com/articles/s4157…

#OncoAlert Available JTO & JTO CRR is a report of B7-H6 as a potential immunotherapy target in #SCLC. Analyzed RNA-seq data from 108 cell lines & 81 pt samples for expression of 39 different checkpoint ligands. B7-H6 seemed the best candidate. #LCSM jto.org/article/S1556-…

In this #ASCO Educational Book📕 we summarize in EGFR mut🫁: ✏️New EGFR TKI options in early stage ✏️New options in metastatic setting ✏️Mechanisms of acquired resistance and new drugs 🧬 online at ascopubs.org/journal/edbk Thanks to Stephanie Saw Xiuning Le MD PhD Lizza Hendriks

🚨T-1 #ASCO24 ASCO! 💪🏼 All set to showcase exciting #NSCLC #LCSM research! #ASCOLung24 ⬇️ Current updated management algorithm for NSCLC, with addition of 1️⃣ Periop Pembrolizumab 2️⃣ Adjuvant Alectinib 3️⃣ Osi/Chemo for EGFRm 4️⃣ Ami/Chemo for EGFR Ex20ins 5️⃣ Repotrectenib ROS1

How to treat advanced NSCLC with driver mutation in 2024 ? @asco #ASCO24

NEW Review: A guide to adaptive immune memory bit.ly/3KyklJG by Donna Farber Nora Lam & YoonSeung Lee provides an overview of current understanding of the phenotype, function, location, generation, maintenance and protective capacity of memory T cells and B cells